

Hospitalizations and emergency visits for Ontario breast cancer patients undergoing neoadjuvant chemotherapy with pembrolizumab: A population-based analysis

G. Ko, M. Castelo, E. Amir, A. Covelli, A. Eskander, V. Freitas, C.A. Koch, Q. Li, , N. Liu, J. Ramruthan, E. Reel, A. Roberts, T. Zhong, and T.D. Cil

Introduction

- Immunotherapy-containing regimens are increasingly used in neoadjuvant treatment for triple negative breast cancer (TNBC)
- Immune-related adverse events may result in:

↑ Hospitalizations ↑ ED visits

OBJECTIVE: To assess the rate of hospitalization and ED visits for breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC) with and without immunotherapy in Ontario, Canada

Methods

Eligibility

Apr 1, 2022 - Aug 31, 2023

- 1301 newly diagnosed BC patients
- Median age of 52 (44 - 62)
- 94.7% with no prior comorbidities

NAC period

Pembrolizumab
n=229




Anti-HER2
n=532

Standard
Chemotherapy
n=540



Post-op period

Results



Conclusion

- BC patients undergoing NAC with pembrolizumab had significantly higher odds of ED visits and hospitalizations before surgery, but not during the post-operative period
- Further research is needed to understand the etiology of unanticipated healthcare use in this patient population and ways to mitigate



Presentation ID: P12

This presentation is the intellectual property of the author/presenter.
Contact them at gary.ko@uhn.ca for permission to reprint and/or distribute.

#SSO2025 | SSO2025.ORG